Condition (MeSH)
Deaf-Blind Disorders
ClinicalTrials.gov lists 55 trials for Deaf-Blind Disorders or a narrower condition beneath it. Laboratoires Thea has the most among industry and government lead sponsors, with 5.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
5 of the 55 trials are tagged with Deaf-Blind Disorders itself; the rest are tagged with a narrower condition beneath it.
When did Deaf-Blind Disorders trials start? (21)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Not applicable
- Observational
Top of scale: 8
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 7 |
| 2025 | 5 |
| 2024 | 4 |
| 2023 | 3 |
| 2022 | 1 |
| 2021 | 8 |
| 2020 | 1 |
| 2019 | 3 |
| 2018 | 3 |
| 2017 | 3 |
Showing 10 of 21 earlier years.
No forecast is made for this condition: it averages 4.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 36 months from start to primary completion across 6 trials still running at the 2026-10-09 snapshot; registered median of 25 months across 20 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Deaf-Blind Disorders trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 2 |
| Phase 1/2 | 6 |
| Phase 2 | 9 |
| Phase 2/3 | 2 |
| Phase 3 | 3 |
| Not applicable | 6 |
| Observational | 27 |
How many Deaf-Blind Disorders trials are recruiting? (8)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 7 |
| Recruiting | 12 |
| Enrolling by invitation | 1 |
| Active, not recruiting | 4 |
| Completed | 19 |
Showing 5 of 8 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Deaf-Blind Disorders trials? (9)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Laboratoires Thea | 5 |
| Nacuity Pharmaceuticals, Inc. | 3 |
| National Eye Institute (NEI) | 3 |
| National Center for Research Resources (NCRR) | 2 |
| Sanofi | 2 |
Showing 5 of 9 sponsors.
Interventions as named in the registry (15)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Sham Procedure | 3 |
| QR-421a | 2 |
| NPI-001 | 2 |
| Intravitreal Injection of Ultevursen | 2 |
| RNA antisense oligonucleotide for intravitreal injection | 1 |
Showing 5 of 15 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Deaf-Blind Disorders trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Total Eye Disorders | 5 | 1 |
| Pregnancy | 2 | 1 |
| Reversible Cardiac Vasospasm | 2 | 1 |
| Secondary Surgical Intervention (excluding Posterior Capsulotomy) | 2 | 1 |
| Clinically Significant Cystoid Macular Edema | 1 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Deaf-Blind Disorders? (2)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Effectiveness of a nurse-supported self-management programme for dual sensory impaired older adults in long-term care: a cluster randomised controlled trial. | BMJ open | 2018 | Yes |
| The expanding spectrum of PRPS1-associated phenotypes: three novel mutations segregating with X-linked hearing loss and mild peripheral neuropathy. | European journal of human genetics : EJHG | 2015 | Yes |
Sub-conditions in MeSH (3)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.